MODULATION OF THE ALTERNATIVE COMPLEMENT PATHWAY BY β1H GLOBULIN*

BY KEITH WHALEY† AND SHAUN RUDDY

(From the Division of Immunology and Connective Tissue Diseases, Department of Medicine, Medical College of Virginia, Health Sciences Division, Virginia Commonwealth University, Richmond, Virginia 23298)

The biologic activities of the major cleavage product of C3 (C3b) are blocked by C3b inactivator, a plasma protein with a mol wt of approximately 100,000 daltons (1) which cleaves C3b into two smaller fragments, C3c and C3d. A second factor which participates in C3b inactivation was provisionally termed C3b inactivator accelerator (A·C3bINA)† (2), because it potentiated the activity of C3b inactivator. The activity of A·C3bINA resides in a plasma protein (3) previously named “β1H globulin” because of its electrophoretic mobility (4). We now describe the purification and some physicochemical characteristics of β1H. In addition, we show that β1H not only potentiates the inactivation of C3b by C3b inactivator but also has two other important regulatory actions. Firstly, it possesses a direct C3b inhibitory activity of its own, distinct from C3b inactivator; and secondly, it directly inhibits the activity of the alternative pathway convertases C3bB and C3bBP formed by the interactions of C3b, properdin (P), and factor B (B) in the presence of factor D.

Materials and Methods

Reagents. The following reagents were obtained from the sources shown: DEAE-cellulose (DE 52) and carboxymethyl cellulose (CM 52) (Reeve Angel, Clifton, N. J.); hydroxyl apatite (Bio-Gel HT), Bio Rex 70, precast polyacrylamide gels, dithiothreitol, and sodium dodecyl sulphate (SDS) (Bio-Rad Laboratories, Richmond, Calif.); quaternary aminoethyl Sephadex A-50 (QAE-Sephadex A-50), sulphopropyl Sephadex G-25 (SP-Sephadex G-25), Sephadex G-200 and G-75, aldolase, and ribonuclease (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.); agarose (Fisher Scientific Co., Pittsburgh, Pa.); trypsin, soybean trypsin inhibitor (SBTI), and five times recrystallized egg albumin (Worthington Biochemical Corp., Freehold, N. J.); zymosan, N-ethyl maleimide (NEMI), and epsilon amino caproic acid (EACA) (Sigma Chemical Co., St. Louis, Mo.); diisopropylfluorophosphate (DFP) (Aldrich Chemical Co., Inc., Milwaukee, Wis.); human or bovine serum albumin (Calbiochem, San Diego, Calif.); human factor XIII (American Red Cross, Bethesda, Md.).

* This work was supported by grants from the National Institutes of Health (nos. AI13049 and AM18976), and an Arthritis Clinical Research Center grant from the Arthritis Foundation. This is publication no. 102 from the Charles W. Thomas Arthritis Fund, Medical College of Virginia.
† Recipient of an H. A. M. Thompson Travelling Fellowship from the Royal College of Physicians of London.

† Abbreviations used in this paper: A, rabbit antibody; A·C3bINA, C3b inactivator accelerator; B, factor B; DFP, diisopropylfluorophosphate; DGVB⁺⁺, mixture of equal volumes of GVB⁺⁺ and D5W⁺⁺; D5W⁺⁺, 5% dextrose in water; E, sheep erythrocytes; EACA, epsilon amino caproic acid; GVB⁺⁺, 0.1% gelatin veronal buffer; NEMI, N-ethyl maleimide; P, properdin; SPTI, soybean trypsin inhibitor; SDS, sodium dodecyl sulphate; Z, average number of hemolytic sites formed per cell.

THE JOURNAL OF EXPERIMENTAL MEDICINE · VOLUME 144, 1976 1147
Modulation of the Alternative Complement Pathway

Buffers. Isotonic veronal-buffered saline containing 0.00015 M Ca++, 0.0005 M Mg++, and 0.1% gelatin veronal buffer (GVB++); 5% dextrose in water containing the same concentrations of divalent cations (D5W++), and a mixture of equal volumes of GVB++ and D5W++ (DGVB++) were prepared (5). D5W-- and GVB-- were made as described above for D5W++ and GVB++, but the divalent cations were omitted. A stock solution of 0.086 M EDTA, pH 7.5, was diluted in GVB-- to prepare 0.04 M EDTA GVB-- and 0.01 M EDTA GVB--. For assays of C3b inactivation, 0.01 M EDTA DGVB--, ionic strength 0.0375 and pH 6.0, was used as previously described (6).

Hemolytic Assays. Guinea pig Cl (5), human C4 (7), C2 (7), C3 (4), C5 (4), B (8), D (8), P (9), and C3b inactivator (1) were purified by previously published techniques. Rat serum (Pel-Freez Biologicals, Inc., Rogers, Ark.) diluted 1:15 in 0.04 M EDTA GVB-- served as a source of C3-C9.

Sheep erythrocytes (E) were sensitized with rabbit antibody (A) and used to produce EAC1 as previously described (7). EAC43 cells bearing limited C3b sites were prepared from EAC14 using purified C2 (50 effective molecules per cell) and limiting amounts of purified C3 followed by treatment in 0.04 M EDTA GVB-- for 2 h at 37°C (6). EAC14 cells bearing limited numbers of C4b sites were prepared by incubating EAC1 (400 effective Cl molecules per cell) with a limiting concentration of C4 at 30°C for 15 min (7). EAC43 cells bearing the unstable alternative pathway convertase, C35B, were prepared by exposing EAC43 cells generated with 1,000 effective molecules of C3 per cell at 30°C for 30 min and a concentration of 5 x 10^7/ml DGVB++ to 5 ng of B/ml and 50 U of D/ml. When required the convertase on these cells was stabilized (10) by treating them at 0°C with 250 ng of P/ml in 0.01 M EDTA GVB--.

To determine the average number of hemolytic C3b sites per erythrocyte, 0.1 ml of EAC43 (1 x 10^9/ml DGVB++) was incubated for 30 min at 30°C with an equal volume of DGVB++ containing 1.0 µg of B and 50 U of factor D. The resulting EAC43B (D) were then incubated for 60 min at 37°C with 0.3 ml of C3-C9. 1.5 ml of 0.15 M NaCl was added, the tubes centrifuged, and the supernatant hemoglobin measured spectrophotometrically at 414 nm. Calculation of the proportion of cells lysed (y), and the average number of hemolytic sites formed per cell (Z) were performed as previously described (11).

For the measurement of the inhibition of cell-bound C3b, equal volumes of EAC43 bearing limited C3b sites and test sample were incubated in 0.01 M EDTA DGVB++ for 1 h, the cells washed once in 0.01 M EDTA GVB--, once in DGVB++, and the residual average number of hemolytic C3b sites determined as described above. Inhibition of hemolysis, which reflects inactivation of C3b, was expressed either as percentage inhibition of hemolytic sites, or alternatively as Z' units where Z' = -ln (1 - proportion of C3b lysis inhibited) (12).

Antisera. Antisera to human Clq (13), C4, C3, and C5, and B (14), P (9), and C3b inactivator (15) were produced and used in radial immunodiffusion as previously described (14). Antisera to IgG, IgA, IgM, α1-macroglobulin, transferrin, β2-glycoproteins I and III, hemopexin, plasminogen, β-lipoprotein, and cholinesterase were purchased from Behring Diagnostics, American Hoechst Corp., Somerville, N. J. Specific F(ab')2 fragments were prepared from monospecific antisera by the method of Lachmann (16).

Analytical Procedures. Immunoelectrophoresis (17) and SDS polyacrylamide gel electrophoresis (18) were performed by standard techniques.

Analytical ultracentrifugation was performed using a Beckman Model E ultracentrifuge (Beckman Instruments, Inc., Spinco Div., Palo Alto, Calif.). The sedimentation coefficient of β1H was determined during centrifugation runs at 80,000 rpm at 20°C in 0.15 M saline buffered with 0.05 M veronal at pH 7.5. To determine the molecular weight of β1H, short-column equilibrium sedimentation studies were performed in an analytical ultracentrifuge at a speed of 9,900 rpm for 24 h at 20°C; a partial specific volume of 0.733 was assumed.

For sucrose density ultracentrifugation, linear gradients of 7.5-30% sucrose in DGVB++ were prepared using a Beckman Gradient mixer (Searle Analytic, Inc., Ft. Lee, N. J.). Centrifugation was performed for 16 h in a Beckman Model L ultracentrifuge at 40,000 rpm and 4°C using an SW50.1 rotor. 0.15 ml samples were collected from the bottom of the gradient at the positions of Clq, C4, C3, IgG, and B determined by radial immunodiffusion. The sedimentation characteristics of β1H in a NaBr gradient were studied by mixing an equal volume of 5.2 M NaBr with β1H at 4 µg/ml veronal-buffered saline to increase the relative density to 1.21 (19), and centrifuging at 39,000 rpm for 48 h in a Beckman Model L ultracentrifuge using an SW39 rotor. The top 25% of the gradient (potentially lipoprotein rich) was removed using a Pasteur pipette, and the lower 75% (potentially lipoprotein depleted) was sampled through the bottom of the tube.
Protein concentrations of pools from column chromatography and purified preparations of β1H were determined using the Folin method (20) with five times recrystallized bovine serum albumin as standard. Immunoadsorbents were prepared by linking the adsorbing material to Sepharose 4B by the cyanogen bromide technique (21).

The sensitivity of β1H to various chemical and physical treatments was tested as follows: 0.1 ml of a solution of 4 μg/ml was treated for 15 min at 37°C with the following reagents at the final concentrations shown: 10⁻³ M DFP, 100 μg/ml SBTI, 10⁻⁵ M NEMI, 10⁻⁴ M I₄, and 1.0 M EACA. To determine the sensitivity of β1H to heat, 4 μg/ml DGVB⁺⁺ were incubated at 56°C for 30 min. Sensitivity to trypsin was tested by treatment with trypsin, 100 μg/ml for 5 min at 37°C followed by the addition of 200 μg/ml of SBTI.

Results

Identification of A·C3bINA Activity in Normal Serum. Because it was repeatedly observed that purified C3b inactivator had less C3b-inactivating activity than the same concentration of C3b inactivator contained in whole serum, other substances in plasma, distinct from C3b inactivator, which could either inactivate C3b directly or potentiate the effect of C3b inactivator, were sought. 2.5 ml of normal human serum were chromatographed on a 2.5 × 90 cm column of Sephadex G-200 in 0.05 M veronal-buffered isotonic saline, pH 7.5, containing 0.01 M EDTA. Direct C3b-inactivating activity was measured by testing fractions with EAC43 bearing 0.8 C3b sites per cell as described in the Materials and Methods. A single peak of C3b-inactivating activity eluted synchronously with C3b inactivator protein detected by radial immunodiffusion at a volume corresponding to a mol wt of approximately 100,000 (Fig. 1). When fractions were tested for their ability to potentiate the C3b inactivation reaction by including 0.4 U of purified C3b inactivator/ml in the assay, a second peak of activity appeared between the 19S and 7S protein peaks in a position corresponding to an approximate mol wt of 300,000 daltons; this was not associated with C3b inactivator protein. The active principal in this early peak, which, under the conditions of the assay, possessed no direct C3b-inactivating activity of its own but potentiated the inactivation of C3b by the C3b inactivator, was tentatively named the C3b inactivator accelerator (A·C3bINA).

Purification of A·C3bINA. 5 U of fresh frozen plasma were thawed and recalcified; clotting was allowed to proceed at 4°C overnight. After separation from the fibrin clot, the serum was dialyzed against 0.008 M EDTA, pH 7.5. The precipitate was separated by centrifugation, and the pH of the supernate reduced to 6.5 by the addition of 1.0 N HCl. After 2 h at 4°C, the precipitate was separated by centrifugation, washed once, redissolved in 0.75 M sodium chloride buffered with 0.25 M veronal at pH 7.5, and dialyzed against 0.01 M Tris HCl containing 0.002 M EDTA, pH 7.5, with sufficient added NaCl to adjust the conductivity to 5.0 mS at 0°C. The dialyzed sample was applied to a QAE-Sephadex A-50 column (2.5 × 100 cm) equilibrated with the same buffer. The column was washed with one column volume of buffer, and then eluted with a linear NaCl gradient increasing to 0.7 M NaCl. As assessed by radial immunodiffusion, C3b inactivator eluted with the starting buffer, behind the initial peak of unadsorbed protein. Using the A·C3bINA assay, two major peaks of C3b inactivation were observed. The first corresponded to C3b inactivator protein, and the second eluted with the gradient at a conductivity of 11.0 mS (0°C) (Fig. 2a). This second peak (fractions 105–115) was concentrated to 15 ml by ultrafil-
MODULATION OF THE ALTERNATIVE COMPLEMENT PATHWAY

Fig. 1. Sephadex G-200 chromatography of normal human serum. 2.5 ml of serum were applied to a 2.5 x 90 cm column. Fractions were assayed for OD280 (-----), Z units of direct C3b-inactivating activity (----), Z' units of C3b inactivator-potentiating activity (----), and presence of C3b inactivator protein (+ at top). RID, radial immunodiffusion.

Concentration, dialyzed against 0.02 M phosphate buffer, pH 7.0, and applied to a BioRex 70 column (2.5 x 35 cm) equilibrated with the same buffer. After the appearance of the unadsorbed protein, a linear NaCl gradient of 0.7 M was applied. A·C3bINA eluted at 11.0 ml (0°C) with the bulk of the adsorbed protein. The A·C3bINA pool (fractions 73-77) was concentrated by ultrafiltration and chromatographed on a Sephadex G-200 column (2.5 x 100 cm) in veronal-buffered saline from which it eluted with an apparent mol wt of 300,000 daltons (Fig. 3). The final pool was concentrated by ultrafiltration to a protein concentration of 395 μg/ml.

Properties of Purified A·C3bINA. In polyacrylamide gel electrophoresis, using 0.188 M Tris-glycine buffer, pH 8.9, purified A·C3bINA failed to enter 7.5% gels, and only partially entered 4% gels, forming a smear near the origin. Incubation of A·C3bINA with 2% SDS and 8.0 M urea at 37°C for 2 h followed by electrophoresis in 4% acrylamide and 0.2% SDS resulted in the presence of a single dense band after staining with Coomassie blue (Fig. 4). This band contained 93% of the stain as determined by densitometry. As judged by comparison with standards of human serum albumin and its polymers, aldolase, ovalbumin, and RNase, the position of the A·C3bINA band corresponded to an approximate mol wt of 150,000 daltons. The appearance of the band was not altered by prior reduction with 0.2 M 2-mercaptoethanol or 0.1 M dithiothreitol in 8.0 M urea followed by incubation with 0.2 M iodoacetamide, suggesting that A·C3bINA is a single polypeptide chain. The band stained heavily in the periodic acid-Schiff (PAS) reaction which indicated that it contained a significant quantity of carbohydrate.

In the analytical ultracentrifuge at a concentration of 367 μg A·C3bINA/ml a single sharp peak was observed which had a sedimentation coefficient of 5.6. This value was unaltered when the protein concentration was reduced to 183.5 μg/ml. By sucrose density gradient ultracentrifugation, the sedimentation coef-
Fro. 2. Purification of A·C3bINA. (a), QAE-Sephadex A-50 separation of pH 6.5 euglobulin of human serum. Fractions were assayed for A·C3bINA activity as described in the text. Two major peaks of C3b inactivation were seen; the early peak, corresponding to C3b inactivator (C3bINA) protein, eluting with the starting buffer; and the second, presumed A·C3bINA, eluting at 11.0 mS at 0°C. RID, radial immunodiffusion. (b), A·C3bINA peak from QAE-Sephadex A-50 rechromatographed over Bio Rex 70. Fractions were assayed for A·C3bINA activity. The single peak of activity eluted at 11.0 mS (0°C) and did not correspond to C3b inactivator (C3bINA) protein. RID, radial immunodiffusion.

Production of Antiserum to A·C3bINA. New Zealand white rabbits were immunized subcutaneously with 100 μg of purified A·C3bINA in Freund's
complete adjuvant. 6 wk later, the animals were reimmunized intravenously with 100 μg of A·C3bINA, and they were bled 7, 10, and 14 days later. On immunoelectrophoresis against whole human plasma, the antiserum produced a dense arc in the β-region and a faint arc in the α-region. Analysis of various fractions of serum indicated that the protein with α-mobility was present in high concentration in the pH 5.4 pseudoglobulin, and that the protein with β-mobility was virtually absent from this fraction. Since preliminary experiments had shown that A·C3bINA activity had a β-mobility in agarose at pH 8.3, the antiserum was adsorbed with insolubilized pH 5.4 pseudoglobulin to render it specific for the protein of β-mobility. In immunoelectrophoresis, this antiserum reacted both with normal human plasma and purified A·C3bINA to yield a single arc in the β-region (Fig. 5) which trailed toward the origin. When agarose strips were cut from the same electrophoresis plate, eluted with DGVB³⁺, and the eluates tested for A·C3bINA activity, the position of this activity corresponded to the precipitin arc.

In double diffusion against normal human serum in agarose gel, the antiserum to A·C3bINA gave reactions of nonidentity with antisera to Clq, C4, C3, B, P, C5, C6, C7, C8, C1 inhibitor, C3b inactivator, β2-glycoproteins I and III, β-lipoprotein, hemopexin, cholinesterase, α2-macroglobulin, plasminogen, transferrin, IgG, IgA, or IgM. No reaction between the antiserum and purified factor XIII was observed. A reaction of identity with antibody to β1H globulin was
initially found by Dr. Chester Alper, Center for Blood Research, Boston, Mass., and subsequently confirmed by Dr. Ulf Nilsson, School of Dental Medicine, University of Pennsylvania, Philadelphia, Pa. β1H was first described as a prominent contaminant of both C3 and C5 preparations (4). A purified sample of β1H from Dr. Nilsson's laboratory had the same electrophoretic, ultracentrifugal, functional, and antigenic properties as our preparations. For the sake of both simplicity and historical accuracy, therefore, the name C3b inactivator accelerator has been discarded and β1H used in its place.

Using monospecific antiserum to β1H we were able to measure the degrees of purification and yields of β1H at various stages during the preparative procedures (Table I). From 1,120 ml of plasma, containing 133 μg of β1H/ml, 2.20 mg of purified β1H were obtained, which is a yield of 1.48%. Since by densitometry only 93% of the Coomassie blue stain was in the β1H band on SDS polyacrylamide gel electrophoresis, we have assumed that the preparation is 93% homogeneous, and that the β1H was purified by a factor of 376.5.

Activity of β1H. The ability of β1H to potentiate the inactivation of C3b by purified C3b inactivator was assessed in the following experiment. Two sets of EAC43 bearing 0.83 hemolytic C3b sites per cell were incubated at 5 × 10⁸/ml 0.01 M EDTA DGVB⁻⁻ in the presence of varying concentrations of β1H, ranging from 0 to 5 μg/ml. One set of cells was incubated with β1H alone, and the other with 0.2 Z¹ U/ml of C3b inactivator in the presence of β1H. At the end of 60 min incubation at 37°C, the extent of C3b inhibition was determined as described in the Materials and Methods. In the absence of C3b inactivator, β1H produced some dose-dependent inhibition of C3b (Fig. 6). C3b inactivator alone reduced the total number of hemolytic sites from 0.83 to 0.69. The extent of inhibition of C3b produced by C3b inactivator and β1H together greatly exceeded the sum of those achieved independently, demonstrating a synergistic effect between these proteins in the inactivation of C3b.

Kinetics of Inactivation of C3b and C3b Inactivator and β1H. Five sets of EAC43 bearing 1.1 C3b sites per cell (1 × 10⁸/ml in 0.01 M EDTA DGVB⁻⁻) were incubated at 37°C with buffer alone, normal serum diluted 1:1,000, purified C3b inactivator containing the same concentration of C3b inactivator as present in the dilution of normal serum, β1H (400 ng/ml), and β1H with C3b inactivator together. Samples were removed from the reaction mixtures at timed intervals, diluted on ice-cold 0.01 M EDTA GVB⁻⁻, and centrifuged. The cells were washed once in DGVB⁺⁺, resuspended to 1 × 10⁸/ml DGVB⁺⁺, and the residual C3b sites
MODULATION OF THE ALTERNATIVE COMPLEMENT PATHWAY

Fig. 5. Agarose gel electrophoresis of A·C3bINA. Upper well, purified A·C3bINA; lower well, normal plasma. A·C3bINA antiserum in upper trough and anti-normal human serum in lower trough. The antiserum produced a single arc in the β-region, which trailed into the origin. Slices were cut from the agarose, eluted, and the eluates tested for A·C3bINA activity as shown in the upper frame. A·C3bINA activity corresponded to immunoprecipitable protein.

TABLE I
Purification of β1H

| Pool            | Volume | Total protein concentration | β1H concentration | Yield at each stage | Purity β1H concentration/protein concentration | Purification factor |
|-----------------|--------|-----------------------------|-------------------|---------------------|-----------------------------------------------|---------------------|
| Plasma          | 1.120  | 53,800                      | 133               | 100.0               | 2.47 × 10^3                                   | –                   |
| Euglobulin, pH 6.5 | 135    | 8,500                       | 490               | 44.4                | 5.76 × 10^2                                   | 23.3                |
| QAE-Sephadex A-50 | 15     | 2,100                       | 741               | 16.8                | 3.53 × 10^1                                   | 142.9               |
| Bio Rex 70      | 3      | 2,200                       | 1,367             | 36.9                | 6.21 × 10^4                                   | 251.4               |
| Sephadex G200   | 6      | 365                         | 597               | 57.8*               | 9.30 × 10^4                                   | 376.5               |

* Total yield of β1H: 2.20 mg, 1.46%.
† This factor is based on densitometric studies of purified β1H on SDS acrylamide gel electrophoresis.

measured. The kinetics of inactivation of C3b (Fig. 7) by C3b inactivator alone, C3b inactivator and β1H together, and normal serum were all first order, suggesting that the potentiation of C3b inactivator by β1H is not a multistep process. β1H alone produced a small amount of inactivation of C3b but the extent of this precluded firm conclusions as to the kinetics of this reaction.

Requirements for the Simultaneous Presence of β1H and C3b Inactivator for the Potentiation of C3b Inactivation. Four identical aliquots of EAC43 bearing 1.1. C3b sites per cell (1 × 10⁹/ml in 0.01 M EDTA DGVB⁻⁻) were incubated at 37°C for 1 h in the presence of either buffer alone, C3b inactivator alone (0.4 Z' U/ml, β1H alone (400 ng/ml), or β1H plus C3b inactivator. The tubes were then centrifuged, the cells washed in 0.01 M EDTA DGVB⁻⁻, resuspended to their original volume, and reincubated for a second hour at 37°C. For the second hour of incubation, the sample initially exposed to C3b inactivator alone was divided into two portions, one of which was incubated in buffer and the second with β1H.
alone. Cells originally exposed to β1H alone were likewise divided into two portions, one being incubated with buffer and the other with C3b inactivator alone. Those cells incubated with C3b inactivator and β1H together during the first hour were incubated with buffer. Cells incubated with buffer during the first hour were reincubated with buffer for a second hour.

C3b inactivator alone produced 48% inactivation of C3b and β1H alone produced 4% inactivation (Fig. 8). Either C3b inactivator followed by β1H, or β1H followed by C3b inactivator yielded inactivation similar to the sum of the values for C3b inactivator and β1H, irrespective of the sequence in which these reagents were used. In contrast, when cells were exposed to β1H and C3b inactivator simultaneously, 87% inactivation was achieved.

**Comparison of Effects on C3b and C4b.** C4b is inactivated by a C4b inactivator, a plasma protein which has not been separated from C3b inactivator (22). The ability of purified C3b inactivator to inactivate cell-bound C3b and C4b, and for β1H to potentiate these effects were compared in the following experiments. EAC43 and EAC14 bearing 1.1 and 1.0 hemolytic sites, respectively, were incubated with varying concentrations of purified C3b inactivator with or without a fixed input of β1H (400 ng/ml). After incubation at 37°C for 1 h in 0.01 M
MODULATION OF THE ALTERNATIVE COMPLEMENT PATHWAY

Fig. 7. Kinetics of inactivation of C3b by normal human serum diluted 1:1,000 (O--O), purified C3b inactivator at the same concentration as present in serum (■—■), β1H alone 400 ng/ml (□—□), and C3b inactivator together with β1H (△—△).

Fig. 8. Requirement for the simultaneous presence of C3b inactivator (C3bINA) and β1H for the β1H potentiation effect. EAC43 were incubated at 37°C for 1 h, with the reagents shown in the upper line. After washing, they were reincubated at 37°C with the reagents shown on the lower line. C3b inactivator alone, C3b inactivator followed by β1H, and β1H followed by C3b inactivator, all produced similar degrees of C3b inactivation. Significant potentiation was only seen when C3b inactivator and β1H were incubated simultaneously.

EDTA DGVB—, the cells were washed twice in DGVB++ and resuspended to 1 × 10⁸/ml DGVB++. The residual C3b sites on EAC43 were developed as previously described. Residual C4b sites on EAC43 produced from the EAC14 by the exposure to EDTA were developed by incubation with C1 (200 U/ml) for 15 min at 30°C, C2 (50 U/ml) for 15 min at 30°C, and finally, in C3–C9 for 1 h at 37°C. C3b inactivator alone produced marked dose-dependent inactivation of C3b but had little effect on C4b (Fig. 9). As anticipated, β1H produced considerable potentiation of C3b inactivation, but little enhancement of the small degree of C4b inactivation was observed.

In the converse experiment (Fig. 10), the input of β1H was varied in the presence or absence of sufficient C3b inactivator to induce almost identical
INPUT OF C3b Inactivator (units/ml)

Fig. 9. Inactivation of C3b and C4b by varied inputs of C3b inactivator and a fixed input of β1H (400 ng/ml). EAC43 showed significant dose-dependent inhibition of C3b by C3b inactivator alone (○—○); β1H markedly enhanced this response (●—●). Little inactivation of C4b was achieved with high inputs of C3b inactivator (△—△) and β1H did not significantly enhance this effect (▲—▲).

INPUT OF β1H (ng/ml)

Fig. 10. Inactivation of C3b and C4b by a fixed input of C3b inactivator and varied inputs of β1H. The inputs of C3b inactivator were adjusted to produce similar degrees of inactivation of C3b (0.4 Z' U/ml) and C4b (40 Z' U/ml). β1H produced dose-dependent enhancement of C3b inactivation by C3b inactivator (●—●), and dose-dependent inhibition of C3b on its own (○—○). Little potentiation of the inactivation of C4b by C3b inactivator (▲—▲), and no direct C4b inhibition (△—△) were observed.

degrees of inactivation of C3b and C4b in the absence of β1H. The input of C3b inactivator required to achieve 43% inactivation of C3b was 0.4 Z' U/ml, whereas that required to produce 52% inactivation of C4b was 40 Z' U/ml. Dose-dependent potentiation of C3b inactivation was observed when β1H was added to the reaction mixtures, but the extent of inactivation of C4b by C3b inactivator was relatively independent of β1H concentration. Significant inhibition of C3b by high concentrations of β1H in the absence of C3b inactivator was observed.

Direct Effect of β1H on C3b. The observations (Figs. 6-10) that high concentrations of β1H inhibited C3b in the absence of C3b inactivator suggested that either β1H had a direct C3b inhibitory activity or the preparation of β1H was contaminated with a small amount of C3b inactivator. To discriminate between these possibilities, the following experiment was performed. Four Z' U of C3b inactivator and 20 μg of β1H were incubated for 15 min at 37°C with an equal volume of F(ab')2 fragments prepared from 5 ml of anti-β1H or anti-C3b inactivator or with buffer. The mixture was then diluted and the residual C3b
inhibitory activity was determined by the inhibition of lysis using the standard assay in which EAC43 were exposed to the mixtures, washed, and developed with B, D, and C3-C9. Anti-β1H removed virtually all of the direct C3b inhibitory activity of β1H, whereas anti-C3b inactivator had little effect (Table II). Conversely, the anti-C3b inactivator removed almost all C3b inactivator activity; but anti-β1H yielded insignificant inhibition. Controls indicated that neither F(ab')2 fragments had any effects on the assay system. In other experiments, anti-β1H removed the C3b inactivator-potentiating activity of β1H. Since the direct C3b inhibitory and C3b inactivator-potentiating activities of β1H were neutralized by specific anti-β1H but not by anti-C3b inactivator, both of these activities reside in the same molecule, β1H.

Effect of β1H on the Alternative Pathway Convertases, C3bB and C3bBP. The capacity of β1H to inhibit a preformed alternative pathway convertase was assessed. EAC43 prepared with 1,000 effective molecules of C3 per cell were incubated at 1 x 10^9/ml DGVB++ for 30 min at 30°C in the presence of 5 ng/ml B and 50 U/ml of D to allow the formation of EAC43bB. The cells were then centrifuged, washed once in ice-cold DGVB++, resuspended to 1 x 10^8/ml in 0.01 M EDTA GVB--, and exposed to 250 ng of P/ml at 0°C to form EAC43bBP. After 3 min at 0°C to allow for binding of P to the EAC43bB, the cells were divided into two portions, one of which received 80 ng/ml of β1H and the other buffer. Both mixtures were then incubated at 30°C and at time intervals 0.1-ml portions were sampled into 0.4 ml of C3-C9 for a further 60-min incubation at 37°C. The half-life of the EAC43bBP suspended in buffer was 17 min, whereas EAC43bBP suspended in β1H exhibited a marked increase in the rate of loss of hemolytic sites (Fig. 11). When EAC43 cells were pretreated with the same concentration of β1H before exposure to B, D, and P for the formation of EAC43bBP, fewer hemolytic sites were observed at time zero, but no increased rate of decay resulted. In other experiments, EAC43bB bearing the labile convertase also exhibited an increased rate of decay upon exposure to β1H. For both convertases, increase in rate of decay was a function of the concentration of β1H.

By contrast, C3b inactivator had no effect on the preformed alternative pathway convertase, as demonstrated in the following experiment. EAC43bBP prepared with 1.5 C3b sites per cell, 10 μg B, 50 U D, and 250 ng P/ml were decayed at 30°C as described in the preceding experiment except that 80 Z' U C3b inactivator were substituted for the β1H. No difference was observed in the rate of decay of EAC43bBP in the presence or absence of C3b inactivator (Fig. 12). As expected, treatment of the EAC43b with C3b inactivator before the formation of the convertase resulted in a decrease of total hemolytic sites at time zero, but no increase in the rate of decay of the EAC43bBP formed on subsequent exposure to B, D, and P was observed.

Discussion

In this paper we have presented evidence that in addition to C3b inactivator there exists in human plasma a second protein which modulates the alternative complement pathway (Fig. 1). On the basis of its ability to potentiate the inactivation of C3b by the C3b inactivator, we originally named this second
Table II
Inhibition of C3b Inhibitory Activities of β1H and C3b Inactivator by
Specific F(ab')2 Fragments

| Reaction mixture       | Z' units observed |          |          |
|------------------------|-------------------|----------|----------|
|                        | Buffer            | F(ab')2 anti-C3b inactivator | F(ab')2 anti-β1H |
| Buffer                 | 0                 | 0        | 0        |
| β1H                    | 0.70              | 0.66     | 0.07     |
| C3b Inactivator        | 0.72              | 0.05     | 0.66     |

Fig. 11. Effect of β1H on the rate of loss of hemolytic sites from EAC3bBP. EAC3bBP were incubated at 30°C in the presence or absence of β1H (80 ng/ml). β1H markedly increased the rate of loss of hemolytic sites. In contrast when EAC43 were treated with β1H before the formation of EAC3bBP, fewer hemolytic sites were found, but the rate of loss of sites was the same as found with the untreated cells.

protein the C3b inactivator accelerator (A·C3bINA). An antiserum to purified A·C3bINA gave a reaction of identity with anti-β1H; β1H being a plasma protein without known function, named on the basis of its electrophoretic mobility (4). For the remainder of the discussion we will use β1H in preference to A·C3bINA.

β1H was purified from the pH 6.5 euglobulin of normal human serum by sequential chromatography on QAE-Sephadex A-50, Bio Rex 70, and Sephadex G-200 (Figs. 2 and 3). The final yield was 1.48% and the purification 376.5-fold (Table I). Three criteria for purity were: a single band on SDS polyacrylamide gel electrophoresis (Fig. 4), a homogeneous peak in the analytical ultracentrifuge, and the ability of the purified protein to produce an antiserum with a high degree of specificity. After the removal by immunoabsorption of a trace contami-
MODULATION OF THE ALTERNATIVE COMPLEMENT PATHWAY

Fig. 12. Effect of C3b inactivator on the rate of loss of hemolytic sites from EAC43bBP. EAC43bBP were incubated at 30°C in the presence (O—O) or absence (•—•) of 80 Z' U/ml of purified C3b inactivator. C3b inactivator did not influence the rate of loss of hemolytic sites. When EAC43 were pretreated with C3b inactivator (△—△), fewer hemolytic sites were detected but the rate of loss of sites was unchanged.

nant in the α-region, the anti-β1H was monospecific (Fig. 5). On agarose electrophoresis, β1H activity was congruent with immunoprecipitable protein (Fig. 5), and F(ab')2 fragments prepared from the anti-β1H antiserum removed this activity (Table II).

On the basis of trypsin sensitivity, β1H is a protein. Since reduction with 0.2 M 2-mercaptoethanol or 0.1 M dithiothreitol failed to alter the number of bands observed during SDS polyacrylamide gel electrophoresis, β1H must be a single polypeptide chain. The PAS-positive nature of the band suggests that β1H contains a significant quantity of carbohydrate. The mol wt of β1H was determined to be approximately 150,000 daltons, both by SDS polyacrylamide gel electrophoresis and by equilibrium sedimentation in the analytical ultracentrifuge. Its elution pattern from Sephadex G-200 corresponds to an approximate mol wt of 300,000 daltons. This discrepancy suggests that the molecule is asymmetric. Since the same sedimentation coefficient of 5.6S was observed during ultracentrifugation at two different β1H concentrations, this asymmetry may be rigid rather than subject to random coil formation as, for example, is DNA. The sedimentation coefficients determined in the analytical ultracentrifuge, 5.6, and in sucrose density gradients, 6.4, are consistent with a mol wt of 150,000, assuming a partial specific volume of 0.733. Since the total carbohydrate content of β1H is at present unknown, the correct mol wt may be significantly lower than 150,000 daltons.

β1H appears to potentiate the inactivation of C3b by C3b inactivator (Figs. 1 and 6–10), to prevent the fruitful interaction of C3b with C5 in the classical and B in the alternative pathways (3), and to diminish the activity of the preformed alternative pathway convertases, C3bB and C3bBP, by increasing their rate of
KEITH WHALEY AND SHAUN RUDDY

decay (Fig. 11). That these activities belong to the same molecule is shown by the ability of immunochemically purified \(\beta 1\)H to produce them, and the reversal of effects on C3b and C3b inactivation by specific F(ab')2 fragments of anti-\(\beta 1\)H (Table II). In its effects on C3b, \(\beta 1\)H resembles C3b inactivator by modulating both classical and alternative pathways. In contrast, however, \(\beta 1\)H is able to inhibit the preformed alternative pathway convertases C3bB and C3bBP (Fig. 11), whereas C3b inactivator is without effect once C3b has interacted with factors B, D, and P (Fig. 12). Another point of differentiation is that C3b inactivator is able to block immune adherence (23), whereas preliminary studies indicate that \(\beta 1\)H does not possess this function.

The ability of \(\beta 1\)H to enhance the inactivation of C3b by C3b inactivator is reminiscent of the action of a "10S globulin" to induce cleavage of C4b by C3b inactivator (24). Further similarity is the necessity for the simultaneous presence of C3b inactivator with either \(\beta 1\)H (Fig. 8) or the 10S globulin for these effects. Although we have not studied the cleavage of C4b, \(\beta 1\)H only weakly potentiates the inactivation of C4b by C3b inactivator (Figs. 9 and 10). A further difference is the sedimentation coefficient of 6.4 for \(\beta 1\)H on sucrose density gradients. Evidence to date suggests that \(\beta 1\)H is not the 10S globulin although appropriate neutralization studies with specific antibodies need to be performed.

In a search for an inhibitor of the preformed alternative pathway convertase, Fearon et al. (unpublished data and personal communication) have identified a protein with this effect; an antiserum to this protein gives a reaction of identity with our anti-\(\beta 1\)H. A "C5-site generation inhibitor" present in guinea pig serum was described in 1969 by Okada et al. (25). This inhibitor could bind with EAC1423 to block C5 activation, but had no effect on immune adherence. These facts, together with a similar elution profile on Sephadex G-200, suggest that the C5-site generation inhibitor is the guinea pig analogue of \(\beta 1\)H.

The mechanism of action of \(\beta 1\)H is not yet understood, but the available evidence suggests that it binds with C3b. Kinetic studies in which both the initial rate and final extent of C3b inhibition are proportional to \(\beta 1\)H concentration suggest a stoichiometric binding rather than an enzymatic reaction. The failure of known enzyme inhibitors such as DFP, SBTI, NEMI, and I2 to block \(\beta 1\)H activity is consistent with this interpretation. Furthermore, EAC43 incubated with \(\beta 1\)H and then washed become agglutinable by anti-\(\beta 1\)H (3). Studies are currently underway to investigate the mechanism of interaction between C3b and \(\beta 1\)H.

Summary

C3b inactivator accelerator (A·C3bINA) was isolated from human plasma. An antiserum produced against the purified protein gave a reaction of identity with \(\beta 1\)H, a well-documented contaminant of C3 preparations. \(\beta 1\)H appears to be composed of a single polypeptide chain containing a significant quantity of carbohydrate, and having a sedimentation coefficient of 5.6 on analytical, and 6.4 on sucrose density gradient ultracentrifugation. Its mol wt based on SDS polyacrylamide gel electrophoresis and equilibrium sedimentation is approximately 150,000, whereas it elutes from Sephadex G200 with an apparent mol wt of 300,000, suggesting that \(\beta 1\)H is an asymmetric molecule.

\(\beta 1\)H potentiates the inactivation of C3b by C3b inactivator, binds to EAC43 to
limit the formation of EAC43βB and EAC43βBP, and in contrast to C3b inactivator, it increases the rate of loss of hemolytic sites from EAC43βB and EAC43βBP. For the C3b inactivator-potentiating effect, β1H and C3b inactivator must necessarily be simultaneously present. The kinetics of inactivation of C3b by C3b inactivator and β1H are first order, suggesting that potentiation is not a multistep process. The mechanisms of binding to C3b and inhibition of the alternative pathway convertases C3βB and C3βBP are currently unknown.

It is a pleasure to acknowledge the analytical ultracentrifuge studies of Dr. A. J. Richard.

Received for publication 23 June 1976.

References

1. Ruddy, S., and K. F. Austen. 1971. C3b Inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b. *J. Immunol.* 107:742.

2. Whaley, K., and S. Ruddy. 1976. C3b inactivator accelerator: a serum cofactor for C3b Inactivator necessary for full expression of its activity. *J. Immunol.* 116:1754. (Abstr.)

3. Whaley, K., and S. Ruddy. 1976. Modulation of C3b hemolytic activity by a plasma protein distinct from C3b inactivator. *Science* (Wash. D. C.). 193:1011.

4. Nilsson, U. R., and H. J. Müller-Eberhard. 1965. Isolation of β1F-globulin from human serum, and its characterization as the fifth component of complement. *J. Exp. Med.* 122:277.

5. Nelson, R. A., J. Jensen, I. Gigli, and N. Tamura. 1966. Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea pig serum. *Immunochemistry.* 3:111.

6. Whaley, K., P. H. Schur, and S. Ruddy. 1976. C3b inactivator in the rheumatic diseases: measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase. *J. Clin. Invest.* 57:1554.

7. Whaley, K., P. H. Schur, and S. Ruddy. 1976. C3b inactivator accelerator: a serum cofactor for C3b Inactivator necessary for full expression of its activity. *J. Immunol.* 116:1754. (Abstr.)

8. Hunsicker, L. G., S. Ruddy, and K. F. Austen. 1973. Alternate complement pathway: factors involved in cobra venom factor (CoVF) activation of the third component of complement (C3). *J. Immunol.* 110:128.

9. Ruddy, S., K. F. Austen, and S. Ruddy. 1967. A stoichiometric assay for the fourth component of complement in whole human serum using EAC′1aαβ and functionally pure human second component. *J. Immunol.* 99:1162.

10. Fearon, D. T., K. F. Austen, and S. Ruddy. 1974. Properdin factor D. II. Activation to D by properdin. *J. Exp. Med.* 140:426.

11. Fearon, D. T., K. F. Austen, and S. Ruddy. 1975. Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. *J. Exp. Med.* 142:856.

12. Rapp, H. J., and T. Borsos. 1970. The Molecular Basis of Complement Action. Appleton-Century-Crofts, New York.

13. Gigli, I., S. Ruddy, and K. F. Austen. 1968. The stoichiometric measurement of the serum inhibitor of the first component of complement by the inhibition of immune hemolysis. *J. Immunol.* 100:1154.

14. Whaley, K., B. Canesi, A. Moseley, W. Morrow, R. Sturrock, W. Mitchell, and W. C. Dick. 1974. Complement metabolism in the seronegative arthritides. *Ann. Rheum. Dis.* 33:495.

15. Rynes, R. I., S. Ruddy, P. H. Schur, J. Spragg, and K. F. Austen. 1974. Levels of complement components, properdin factors, and kininogen in patients with inflammatory arthritides. *J. Rheumatol.* 1:413.
Further purification and production of antibody to C3bINA. *J. Immunol.* 108:657.

16. Lachmann, P. J. 1971. The purification of specific antibody as F(ab')2, by the pepsin digestion of antigen-antibody precipitates, and its application to immunoglobulin and complement antigens. *Immunochimistry.* 8:81.

17. Wieme, R. J. 1959. An improved technique of agar-gel electrophoresis on microscope slides. *Clin. Chim. Acta* 4:317.

18. Weber, W., and M. Osborn. 1969. The reliability of molecular weight determinations by dodecyl sulphate-polyacrylamide gel electrophoresis. *J. Biol. Chem.* 244:4406.

19. Dalmasso, A. P., and H. J. Müller-Eberhard. 1967. Physicochemical characteristics of the third and fourth component of complement after dissociation from complement-cell complexes. *Immunology.* 13:293.

20. Lowry, O. H., N. J. Rosebrough, L. Farr, and R. J. Randall. 1951. Protein measurement with the folin phenol reagent. *J. Biol. Chem.* 193:265.

21. Goetzl, E. J., and H. Metzger. 1970. Affinity labelling of a mouse myeloma protein which binds nitrophenyl ligands. Kinetics of labelling and isolation of a labeled peptide. *Biochemistry.* 9:1267.

22. Cooper, N. R. 1975. Isolation and analysis of the mechanism of action of an inactivator of C4b in normal human serum. *J. Exp. Med.* 141:890.

23. Gigli, I., and R. A. Nelson, Jr. 1968. Complement dependent immune phagocytosis. I. Requirements for C'1, C'4, C'2, C'3. *Exp. Cell Res.* 51:45.

24. Shiraishi, S., and R. M. Stroud. 1975. Cleavage products of C4b produced by enzymes in human serum. *Immunochimistry.* 12:935.

25. Okada, H., S. Kawachi, and K. Nishioka. 1969. A new complement inhibitor in guinea pig serum. *Jpn. J. Exp. Med.* 39:527.